1. Catalog
  2. GRLABRMG2601 - CME/CMLE - Laboratory Readiness for ...
GRLABRMG2601 - CME/CMLE - Laboratory Readiness for Cancer Biomarker Testing: Immunohistochemistry (IHC)
Course Description

Laboratory Readiness for Cancer Biomarker Testing: Immunohistochemistry (IHC) 

This webinar is designed to enhance laboratory readiness for cancer biomarker testing, with a focused deep dive into immunohistochemistry (IHC). Led by expert pathologists and laboratory professionals, this session will draw on extensive real-world experience to support laboratories in implementing, optimizing, and standardizing IHC protocols for cancer biomarker detection. 

Course topics include: 

  • Assessing laboratory operational readiness for new cancer IHC biomarker assays 

  • Regulatory and validation requirements for IHC testing 

  • Strategic implementation decisions 

  • Analytical performance and quality assurance 

  • Compliant reporting and pathologist preparedness 

Target Audience 
This activity has been designed to meet the educational needs of pathologists and laboratory professionals.     


Credit Designation Statement
The ASCP designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.   

ASCP designates this activity for a maximum of 1.0 CMLE credit.  This activity meets CMP and state re-licensure requirements for laboratory personnel.   

For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, option 2, in the US & Canada or internationally at access code + 3-1-312-541-4890. Monday-Friday, 8am-5pm CT. 


Method of Participation
To complete the activity and receive credit, the participant must participate in the live webinar. CME certificates will be provided online.  

Commercial Support
This activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.  


Faculty/Authors

Georgios Defteros, MD, FASCP
Professor, Pathology; Associate Director, Clinical Cancer Genomics Laboratory; Director, Molecular Cytopathology
University of California, San Francisco 

Karla Valencia, MBA, QIHC, HT(ASCP)
Laboratory Manager
MD Anderson Cancer Center
Houston, Texas 

Physician Competencies: Patient Care, Medical Knowledge


CME/CMLE Credit: 1.0
Estimated Completion Time: 1 hour
Format: Online educational activity

Instructions

To claim CME/CMLE credit for the exercise, do the following:

  1. Review the Technical Considerations.
  2. Review and Submit the Demoraphic Survey
  3. Submit the course Evaluation.
  4. Enter the number of credits claimed and click Claim CME/CMLE to register credit.

 Faculty Disclosure

 Technical Considerations 

Release Dates:  2/25/2026     
Review Date:
Expiration Date: 3/25/2026     

Course Objectives

Upon completion of this activity, you will be able to:

  • Assess laboratory readiness for implementing new cancer IHC biomarker assays 

  • Analyze operational and financial considerations for IHC implementation 

  • Differentiate regulatory pathways and validation requirements for IHC assays 

  • Explain the clinical and regulatory significance of IHC biomarkers in oncology 

  • Identify resources and strategies to improve laboratory readiness for cancer IHC biomarker testing 

 


 


  

 
Summary
Availability:
On-Demand
Credit Offered:
1 CME/CMLE Credit
Powered By